HK1105536A1 - Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors - Google Patents
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitorsInfo
- Publication number
- HK1105536A1 HK1105536A1 HK07110750.2A HK07110750A HK1105536A1 HK 1105536 A1 HK1105536 A1 HK 1105536A1 HK 07110750 A HK07110750 A HK 07110750A HK 1105536 A1 HK1105536 A1 HK 1105536A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibitors
- map kinase
- triazolopyridinylsulfanyl
- derivatives
- triazolopyridinylsulfanyl derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0418015A GB0418015D0 (en) | 2004-08-12 | 2004-08-12 | New compounds |
US69155905P | 2005-06-17 | 2005-06-17 | |
PCT/IB2005/002574 WO2006018718A2 (en) | 2004-08-12 | 2005-08-09 | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1105536A1 true HK1105536A1 (en) | 2008-02-15 |
Family
ID=35783420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07110750.2A HK1105536A1 (en) | 2004-08-12 | 2007-10-04 | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
Country Status (35)
Country | Link |
---|---|
US (2) | US7511057B2 (nl) |
EP (1) | EP1778686B9 (nl) |
JP (1) | JP4084836B2 (nl) |
AP (1) | AP2326A (nl) |
AR (1) | AR050692A1 (nl) |
AT (1) | ATE412652T1 (nl) |
AU (1) | AU2005273612B2 (nl) |
BR (1) | BRPI0514255A (nl) |
CA (1) | CA2576297C (nl) |
CR (1) | CR8918A (nl) |
CU (1) | CU23497A3 (nl) |
CY (1) | CY1108788T1 (nl) |
DE (1) | DE602005010714D1 (nl) |
DK (1) | DK1778686T3 (nl) |
EA (1) | EA012119B1 (nl) |
EC (1) | ECSP077232A (nl) |
ES (1) | ES2314690T3 (nl) |
GE (1) | GEP20104973B (nl) |
GT (1) | GT200500218A (nl) |
HK (1) | HK1105536A1 (nl) |
HN (1) | HN2005000418A (nl) |
HR (1) | HRP20080608T3 (nl) |
IL (1) | IL181047A (nl) |
MA (1) | MA28798B1 (nl) |
MX (1) | MX2007001759A (nl) |
MY (1) | MY140021A (nl) |
NL (1) | NL1029726C2 (nl) |
NO (1) | NO339320B1 (nl) |
NZ (1) | NZ552868A (nl) |
PL (1) | PL1778686T3 (nl) |
PT (1) | PT1778686E (nl) |
SI (1) | SI1778686T1 (nl) |
SV (1) | SV2006002193A (nl) |
TN (1) | TNSN07050A1 (nl) |
WO (1) | WO2006018718A2 (nl) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7579360B2 (en) * | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
WO2007091152A1 (en) * | 2006-02-09 | 2007-08-16 | Pfizer Limited | Triazolopyridine compounds |
JP5244369B2 (ja) * | 2006-11-10 | 2013-07-24 | 富士フイルム株式会社 | 5−アミノピラゾール誘導体の製造方法、アゾ色素 |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
US8119658B2 (en) * | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
ES2423991T3 (es) * | 2008-02-04 | 2013-09-26 | Pfizer Limited | Forma polimórfica de un derivado de [1,2,4]triazolo[4,3-a]piridina para el tratamiento de enfermedades inflamatorias |
US8498729B2 (en) | 2008-08-29 | 2013-07-30 | Smp Logic Systems Llc | Manufacturing execution system for use in manufacturing baby formula |
WO2010029167A2 (en) * | 2008-09-12 | 2010-03-18 | Universitätsklinikum Münster | Means and methods for evaluating a therapy with a p38 map kinase inhibitor |
EP2398798A1 (en) | 2009-02-17 | 2011-12-28 | CHIESI FARMACEUTICI S.p.A. | Triazolopyridine derivatives as p38 map kinase inhibitors |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
WO2010141796A2 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
JP5787977B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | P38mapキナーゼ阻害剤 |
WO2011158044A2 (en) | 2010-06-17 | 2011-12-22 | Respivert Limited | Respiratory formulations and compounds for use therein |
US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
EP2763984B1 (en) | 2011-10-03 | 2016-04-20 | Respivert Limited | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors |
EP2788348B1 (en) | 2011-12-09 | 2016-10-19 | Chiesi Farmaceutici S.p.A. | Kinase inhibitors |
RU2586333C1 (ru) | 2011-12-09 | 2016-06-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта |
CA2858447C (en) | 2011-12-09 | 2020-10-27 | Monique Bodil Van Niel | Tryazolopyridine derivatives as kinase inhibitors |
GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
KR20160016973A (ko) * | 2013-06-06 | 2016-02-15 | 키에시 파르마슈티시 엣스. 피. 에이. | P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체 |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
AU2018346712B2 (en) | 2017-10-05 | 2021-04-01 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
KR20210146290A (ko) | 2019-02-12 | 2021-12-03 | 스미토모 다이니폰 파마 온콜로지, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3050525A (en) * | 1960-12-14 | 1962-08-21 | John B Bicking | Certain derivatives of s-triazolo [4, 3-a]-pyridine |
US3754887A (en) * | 1969-05-05 | 1973-08-28 | Du Pont | Ureidopyrazoles defoliants |
US4183854A (en) * | 1976-11-10 | 1980-01-15 | John Wyeth & Brother Limited | Thiazole compound |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
JP2627348B2 (ja) * | 1990-03-16 | 1997-07-02 | セイコー電子工業株式会社 | ラインサーマルプリンタ |
JPH11503110A (ja) | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体拮抗剤 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
EA004771B1 (ru) | 1996-04-23 | 2004-08-26 | Вертекс Фармасьютикалз Инкорпорейтед | Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
DE69720051T2 (de) * | 1996-12-03 | 2003-09-04 | Banyu Pharma Co Ltd | Harnstoffderivate |
US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
BR9809451A (pt) | 1997-05-22 | 2000-06-20 | Searle & Co | Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38. |
ID22982A (id) | 1997-05-22 | 1999-12-23 | Searle & Co | PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38 |
US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
KR100571588B1 (ko) | 1997-12-22 | 2006-04-17 | 바이엘 코포레이션 | 치환 헤테로시클릭 우레아를 이용한 raf 키나제의 억제 |
CA2331878A1 (en) | 1998-05-14 | 1999-11-18 | G.D. Searle & Co. | 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors |
AU8238298A (en) | 1998-07-30 | 2000-02-21 | Gulserene Dastur | Weather-proof furniture system mainly for outdoor use |
US6350744B1 (en) | 1998-11-20 | 2002-02-26 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
US6469018B1 (en) | 1999-01-08 | 2002-10-22 | Smithkline Beecham Corporation | Compounds |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
US6525046B1 (en) * | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
WO2001057038A1 (de) * | 2000-02-01 | 2001-08-09 | Basf Aktiengesellschaft | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
US7978329B2 (en) | 2000-08-02 | 2011-07-12 | Honeywell International Inc. | Portable scattering and fluorescence cytometer |
ES2260415T3 (es) * | 2001-03-09 | 2006-11-01 | Pfizer Products Inc. | Triazolopiridinas como agentes antiimflamatorios. |
EP1408950B1 (en) | 2001-07-11 | 2007-04-25 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of treating cytokine mediated diseases |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
WO2003059891A1 (en) | 2002-01-18 | 2003-07-24 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
WO2003068223A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
PL218749B1 (pl) | 2002-02-14 | 2015-01-30 | Pharmacia Corp | Pochodna pirydynonu oraz jej zastosowanie do wytwarzania leku |
EP1495016A2 (en) | 2002-04-09 | 2005-01-12 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
MXPA04011638A (es) | 2002-06-05 | 2005-03-07 | Pharmacia Corp | Derivados de pirazol como inhibidores de la quinasa p38. |
US20060063782A1 (en) | 2002-07-03 | 2006-03-23 | Murray Christopher W | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors |
MXPA05008568A (es) * | 2003-02-14 | 2005-11-04 | Pfizer Prod Inc | Nuevos compuestos anti-inflamatorios triazolo-piridinas. |
CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
WO2004078116A2 (en) | 2003-03-03 | 2004-09-16 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
GB0320244D0 (en) | 2003-05-06 | 2003-10-01 | Aventis Pharma Inc | Pyrazoles as inhibitors of tumour necrosis factor |
-
2005
- 2005-08-09 EA EA200700219A patent/EA012119B1/ru not_active IP Right Cessation
- 2005-08-09 DE DE602005010714T patent/DE602005010714D1/de active Active
- 2005-08-09 JP JP2007525382A patent/JP4084836B2/ja not_active Expired - Fee Related
- 2005-08-09 BR BRPI0514255-5A patent/BRPI0514255A/pt not_active IP Right Cessation
- 2005-08-09 AU AU2005273612A patent/AU2005273612B2/en not_active Ceased
- 2005-08-09 WO PCT/IB2005/002574 patent/WO2006018718A2/en active Application Filing
- 2005-08-09 SI SI200530498T patent/SI1778686T1/sl unknown
- 2005-08-09 PL PL05772546T patent/PL1778686T3/pl unknown
- 2005-08-09 ES ES05772546T patent/ES2314690T3/es active Active
- 2005-08-09 PT PT05772546T patent/PT1778686E/pt unknown
- 2005-08-09 EP EP05772546A patent/EP1778686B9/en active Active
- 2005-08-09 DK DK05772546T patent/DK1778686T3/da active
- 2005-08-09 AP AP2007003905A patent/AP2326A/xx active
- 2005-08-09 NZ NZ552868A patent/NZ552868A/en not_active IP Right Cessation
- 2005-08-09 AT AT05772546T patent/ATE412652T1/de active
- 2005-08-09 CA CA2576297A patent/CA2576297C/en not_active Expired - Fee Related
- 2005-08-09 GE GEAP20059863A patent/GEP20104973B/en unknown
- 2005-08-09 MX MX2007001759A patent/MX2007001759A/es active IP Right Grant
- 2005-08-10 HN HN2005000418A patent/HN2005000418A/es unknown
- 2005-08-10 US US11/201,823 patent/US7511057B2/en not_active Expired - Fee Related
- 2005-08-10 MY MYPI20053731A patent/MY140021A/en unknown
- 2005-08-11 AR ARP050103357A patent/AR050692A1/es unknown
- 2005-08-11 GT GT200500218A patent/GT200500218A/es unknown
- 2005-08-12 NL NL1029726A patent/NL1029726C2/nl not_active IP Right Cessation
- 2005-08-12 SV SV2005002193A patent/SV2006002193A/es unknown
-
2007
- 2007-01-29 IL IL181047A patent/IL181047A/en not_active IP Right Cessation
- 2007-02-08 CU CU20070042A patent/CU23497A3/es active IP Right Grant
- 2007-02-09 EC EC2007007232A patent/ECSP077232A/es unknown
- 2007-02-09 CR CR8918A patent/CR8918A/es unknown
- 2007-02-09 TN TNP2007000050A patent/TNSN07050A1/fr unknown
- 2007-02-12 MA MA29676A patent/MA28798B1/fr unknown
- 2007-03-07 NO NO20071242A patent/NO339320B1/no not_active IP Right Cessation
- 2007-10-04 HK HK07110750.2A patent/HK1105536A1/xx not_active IP Right Cessation
-
2008
- 2008-11-24 HR HR20080608T patent/HRP20080608T3/xx unknown
- 2008-12-01 CY CY20081101380T patent/CY1108788T1/el unknown
-
2009
- 2009-02-16 US US12/371,719 patent/US8076356B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1105536A1 (en) | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors | |
IL189264A0 (en) | p38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | |
IL189356A0 (en) | p38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | |
IL177278A0 (en) | Pyrazolotriazines as kinase inhibitors | |
IL189374A0 (en) | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | |
IL187310A0 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
AP2048A (en) | Diazepinoindole derivatives as kinase inhibitors | |
IL172132A0 (en) | Thienopyridone derivatives as kinase inhibitors | |
EP1794137A4 (en) | SPECIFIC KINASE INHIBITORS | |
IL173381A0 (en) | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | |
IL189381A0 (en) | P38 map kinase inhibitors and methods for using the same | |
HK1163677A1 (zh) | 可用作激酶抑制劑的吡唑基氨基吡啶衍生物 | |
PL1763517T3 (pl) | Pochodne pirymidyny jako inhibitory 11BETA-HSD1 | |
IL183276A0 (en) | Kinase inhibitors | |
EP1778693A4 (en) | AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL | |
HK1100141A1 (en) | Kinase inhibitors | |
IL188027A0 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
IL189382A0 (en) | p38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | |
EP1713793A4 (en) | PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS | |
ZA200700923B (en) | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | |
ZA200703835B (en) | Heterocyclic substituted bisarylurea derivatives as kinase inhibitors | |
ZA200608998B (en) | Imidazole derivatives as tyrosine kinase inhibitors | |
ZA200809361B (en) | p38 MAP kinase inhibitors | |
ZA200803288B (en) | Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors | |
GB0621831D0 (en) | Inhibitors of p38 map kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170809 |